Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 7Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors, Adult 1Skin Neoplasms 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Interleukin-2 9Melphalan 8CTLA-4 Antigen 8sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7tebentafusp 6Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Bevacizumab 5aldesleukin 4aflibercept 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Blood Specimen Collection 4Biopsy 4trametinib 3sotrastaurin 3relatlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uveal Melanoma × Toll-Like Receptor 1 × Clear all
NCT05576077 2025-03-10

STARLING

Turnstone Biologics, Corp.

Phase 1 Terminated
31 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡